Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.54 |
| ▸ | DRD3 | P35462 | 9/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12363792 | 0.86 | DRD2 (0.66) | DRD2DRD3MAPK1GRM5CYP2C19 | |
| Propionic Acid SCHEMBL29011051 | 0.86 | MAPK1 (0.50) | DRD2DRD3MAPK1GRM5CYP2C19 | |
| SCHEMBL740117 | 0.85 | DRD2 (0.54) | DRD2DRD3MAPK1GRM5CYP2C19 | |
| SCHEMBL742988 | 0.84 | — | — | |
| SCHEMBL1252787 | 0.81 | MAPK1 (0.42) | DRD2DRD3MAPK1GRM5 | |
| SCHEMBL27289803 | 0.78 | DRD2 (0.59) | DRD2DRD3MAPK1GRM5DRD4 | |
| SCHEMBL22736597 | 0.77 | DRD2 (0.50) | DRD2DRD3MAPK1GRM5FGFR1 | |
| SCHEMBL17613234 | 0.77 | DRD2 (0.50) | DRD2DRD3MAPK1GRM5FGFR1 | |
| SCHEMBL13937962 | 0.77 | MAPK1 (0.47) | DRD2DRD3MAPK1GRM5FGFR1 | |
| SCHEMBL13940002 | 0.77 | DRD2 (0.58) | DRD2DRD3MAPK1GRM5CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552172-A | Edison (R) sarban Synthesis method of intermediate | 浙江美诺华药物化学有限公司 | 2025-03-04 | — | — | CN | claimed |
| CN-117384186-A | Synthesis method of intermediate for preparing edoxaban | 沧州那瑞化学科技有限公司 | 2024-01-12 | — | — | CN | claimed |
| US-7880005-B2 | reacting 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine with an alkali metal nitrite in the presence of a reducing agent in an aqueous solution of an acidic compound; hydrolysis; industrial scale | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-01 | — | — | US | claimed |
| US-20100076192-A1 | PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | claimed |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| CN-119751479-A | Edison (R) sarban Synthesis method of intermediate | 沧州那瑞化学科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119552172-A | Edison (R) sarban Synthesis method of intermediate | 浙江美诺华药物化学有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119552172-A | Edison (R) sarban Synthesis method of intermediate | 浙江美诺华药物化学有限公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240092792-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | US | disclosed |
| CN-117384186-A | Synthesis method of intermediate for preparing edoxaban | 沧州那瑞化学科技有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076192-A1 | PROCESS FOR PRODUCING 5-METHYL-4,5,6,7-TETRAHYDROTHIAZOLO[5,4-c]PYRIDINE-2-CARBOXYLIC ACID | NOX4, NOX5, NOS2 | DRD2 3556/4885DRD3 4485/4885MAPK1 719/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | DRD2 702/4885DRD3 713/4885MAPK1 1349/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | DRD2 351/4885DRD3 353/4885MAPK1 1864/4885 |
| US-20240092792-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | DRD2 3255/4885DRD3 3530/4885MAPK1 263/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | DRD2 351/4885DRD3 353/4885MAPK1 1864/4885 |
| US-12534474-B2 | Dihydrofuropyridine derivatives as rho-kinase inhibitors | ROCK1, RHOC, ROCK2 | DRD2 2801/4885DRD3 2229/4885MAPK1 119/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | DRD2 351/4885DRD3 353/4885MAPK1 1864/4885 |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | DRD2 3255/4885DRD3 3530/4885MAPK1 263/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | DRD2 294/4885DRD3 283/4885MAPK1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.